Aldawsari, M., Almadani, F.A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023). The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity, 16:575-595. https://doi.org/10.2147/DMSO.S387116

Alkhatib, N.S., Almutairi, A.R., Alkhezi, O.S., Alfayez, O.M., Al Yami, M.S., & Almohammed, O.A. (2022). Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharmaceutical Journal, 30(4):433-439. https://doi.org/10.1016/j.jsps.2022.01.018

Alqahtani, S.A., Al-Omar, H.A., Alshehri, A., Abanumay, A., Alabdulkarim, H., Alrumaih, A., et al. (2023). Obesity burden and impact of weight loss in Saudi Arabia: A modelling study. Advances in Therapy, 40(3):1114-1128. https://doi.org/10.1007/s12325-022-02415-8

Al-Sabah, S., ElShamy, A., Jois, S., Low, K., Gras, A., & Gulnar, E.P. (2023). The economic impact of obesity in Kuwait: A micro-costing study evaluating the burden of obesity-related comorbidities. Journal of Medical Economics, 26(1):1368-1376. https://doi.org/10.1080/13696998.2023.2265721

American Diabetes Association Professional Practice Committee. (2025a). 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl 1):S27-S49. https://doi.org/10.2337/dc25-S002

American Diabetes Association Professional Practice Committee. (2025b). 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl 1):S167-S180. https://doi.org/10.2337/dc25-S008

Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A.M., Sadhu, A., et al. (2022). Efficacy of semaglutide in treating obesity: A systematic review of randomized controlled trials (RCTs). Cureus, 14(12):e32610. https://doi.org/10.7759/cureus.32610

Angelis, A., Lange, A., & Kanavos, P. (2018). Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics, 19(1):123-152. https://doi.org/10.1007/s10198-017-0871-0

Benney, T., & Cohen, B. (2022). The international currency system revisited. Review of Keynesian Economics, 10(4):443-461.

Chantzaras, A.E., & Yfantopoulos, J.N. (2018). Financial protection of households against health shocks in Greece during the economic crisis. Social Science and Medicine, 211:338-351. https://doi.org/10.1016/j.socscimed.2018.06.024

Choi, J.G., Winn, A.N., Skandari, M.R., Franco, M.I., Staab, E.M., Alexander, J., et al. (2022). First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A cost-effectiveness study. Annals of Internal Medicine, 175(10):1392-1400. https://doi.org/10.7326/M21-2941

Ciardullo, S., Savare, L., Rea, F., Perseghin, G., & Corrao, G. (2024). Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 40(4):e3791. https://doi.org/10.1002/dmrr.3791

D’Andrea, E., Wexler, D.J., Kim, S.C., Paik, J.M., Alt, E., & Patorno, E. (2023). Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Internal Medicine, 183(3):242-254. https://doi.org/10.1001/jamainternmed.2022.6664

De Bromhead, A., Jordan, D., Kennedy, F., & Seddon, J. (2023). Sterling’s farewell symphony: The end of the Sterling Area revisited. The Economic History Review, 76(2):415-444. https://doi.org/10.1111/ehr.13175

Durden, E., Liang, M., Fowler, R., Panton, U.H., & Mocevic, E. (2019). The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. Journal of Managed Care and Specialty Pharmacy, 25(6):669-680. https://doi.org/10.18553/jmcp.2019.18429

Evans, M., Engberg, S., Faurby, M., Fernandes, J., Hudson, P., & Polonsky, W. (2022). Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism, 24(3):377-390. https://doi.org/10.1111/dom.14603

Filippatos, T.D., Panagiotopoulou, T.V., & Elisaf, M.S. (2014). Adverse effects of GLP-1 receptor agonists. The Review of Diabetic Studies, 11(3-4):202-230. https://doi.org/10.1900/RDS.2014.11.202

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., et al. (2020). Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences, 21(17):6275. https://doi.org/10.3390/ijms21176275

Gallwitz, B. (2019). Clinical use of DPP-4 inhibitors. Frontiers in Endocrinology (Lausanne), 10:389. https://doi.org/10.3389/fendo.2019.00389

Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., et al. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 13:935823. https://doi.org/10.3389/fphar.2022.935823

Garcia-Casares, N., Gonzalez-Gonzalez, G., de la Cruz-Cosme, C., Garzon-Maldonado, F.J., de Rojas-Leal, C., Ariza, M.J., et al. (2023). Effects of GLP-1 receptor agonists on neurological complications of diabetes. Reviews in Endocrine and Metabolic Disorders, 24(4): 655-672. https://doi.org/10.1007/s11154-023-09807-3

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). (2021). Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: A cost-effectiveness and price target analysis. Lancet Diabetes Endocrinology, 9(12):825-836. https://doi.org/10.1016/S2213-8587(21)00240-0

Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., et al. (2023). Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 14:1102792. https://doi.org/10.3389/fphar.2023.1102792

Guan, R., Yang, Q., Yang, X., Du, W., Li, X., & Ma, G. (2022). Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. Frontiers in Pharmacology, 13:998816. https://doi.org/10.3389/fphar.2022.998816

Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023). A comprehensive review on weight loss associated with anti-diabetic medications. Life (Basel), 13(4):1012. https://doi.org/10.3390/life13041012

Hu, K., Huang, H., Li, H., Wei, Y., & Yao, C. (2023). Legume-derived bioactive peptides in type 2 diabetes: Opportunities and challenges. Nutrients, 15(5):1096. https://doi.org/10.3390/nu15051096

Karagiannis, T., Bekiari, E., & Tsapas, A. (2023). Socioeconomic aspects of incretin-based therapy. Diabetologia, 66(10):1859- 1868. https://doi.org/10.1007/s00125-023-05962-z

Kennedy, C., Hayes, P., Salama, S., Hennessy, M., & Fogacci, F. (2023). The effect of semaglutide on blood pressure in patients without diabetes: A systematic review and meta-analysis. Journal of Clinical Medicine, 12(3):772. https://doi.org/10.3390/jcm12030772

Lane, P., & Milesi-Ferretti,G.M. (2018). The External Wealth of Nations Revisited: International Financial Integration in the Aftermath of the Global Financial Crisis. IMF Economic Review. Vol. 66. Palgrave Macmillan: International Monetary Fund, p.189-222. https://doi.org/10.1057/s41308-017-0048-y

Laursen, H.V.B., Jorgensen, E.P., Vestergaard, P., & Ehlers, L.H. (2023). A systematic review of cost-effectiveness studies of newer non-insulin antidiabetic drugs: Trends in decision-analytical models for modelling of type 2 diabetes mellitus. Pharmacoeconomics, 41(11):1469-1514. https://doi.org/10.1007/s40273-023-01268-5

Lee, D.S.U., & Lee, H. (2022). Adherence and persistence rates of major antidiabetic medications: A review. Diabetology and Metabolic Syndrome, 14(1):12. https://doi.org/10.1186/s13098-022-00785-1

Ling, J., Chen, S., Zahry, N.R., & Kao, T.A. (2023). Economic burden of childhood overweight and obesity: A systematic review and meta-analysis. Obesity Reviews, 24(2):e13535. https://doi.org/10.1111/obr.13535

Lv, L., Brady, B.L., Xie, L., Guevarra, M., & Turchin, A. (2024). Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Primary Care Diabetes, 18(5):511-517. https://doi.org/10.1016/j.pcd.2024.06.013

Ma, H., Lin, Y.H., Dai, L.Z., Lin, C.S., Huang, Y., & Liu, S.Y. (2023). Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: A systematic review and network meta-analysis. BMJ Open, 13(3):e061807. https://doi.org/10.1136/bmjopen-2022-061807

McCoy, R.G., Van Houten, H.K., Deng, Y., Mandic, P.K., Ross, J.S., Montori, V.M., et al. (2021). Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019. JAMA Network Open, 4(2):e2035792. https://doi.org/10.1001/jamanetworkopen.2020.35792

Mentis, I. (2022). Impact of health indicators and socio-economic inequalities on Greek population’s health level in relation to causes. Acta Scientific Medical Sciences, 6(4):3-12.

Mentis, Ι. (2021). The market of generic drugs in Southern Europe with the contribution of health technology assessment and competition. Arch Hellenic Medicine, 38:89-94.

Mentis, Ι. (2022). The introduction of health technology assessment (HTA) in Greece and comparison with the European experience. Archives of Hellenic Medicine/ ArheiaEllenikesIatrikes, 39(3):313-321.

Mentis, Ι. (2023). Correlation between the Greek gross domestic product and health expenditure during the financial crisis, with emphasis on reimbursement of the cost of diabetic health materials by the National Organization for Healthcare Services Provision. Archives of Hellenic Medicine, 40(2):260-269.

Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., et al. (2023). Adverse events related to tirzepatide. Journal of the Endocrine Society, 7(4):bvad016. https://doi.org/10.1210/jendso/bvad016

Morfonios, A., Kaitelidou, D., Baltopoulos, G., & Myrianthefs, P. (2013). The international practice of health technology assessment. Archives of Hellenic Medicine/ ArheiaEllenikesIatrikes, 30(1):19-34.

Morton, J.I., Marquina, C., Shaw, J.E., Liew, D., Polkinghorne, K.R., Ademi, Z., et al. (2023). Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: A cost-effectiveness analysis. Diabetologia, 66(4):642-656. https://doi.org/10.1007/s00125-022-05832-0

Mossialos, E., & Le Grand, J. (Eds.). (2019). Health Care and Cost Containment in the European Union. London: Routledge.

Nauck, M.A., & Dietrich, J.W. (2022). Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status. The Lancet Regional Health, 14:100318. https://doi.org/10.1016/j.lanepe.2022.100318

Ofori-Asenso, R., Ilomaki, J., Chin, K.L., Mazidi, M., Zomer, E., Bell, J.S., et al. (2019). Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice, 158:107909. https://doi.org/10.1016/j.diabres.2019.107909

Ofori-Asenso, R., Sahle, B.W., Chin, K.L., Mazidi, M., Ademi, Z., De Bruin, M.L., et al. (2021). Poor adherence and persistence to sodium glucose cotransporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis. Diabetes Metabolism Research and Reviews, 37(1):e3350. https://doi.org/10.1002/dmrr.3350

Ogundipe, O., Mazidi, M., Chin, K.L., Gor, D., McGovern, A., Sahle, B.W., et al. (2021). Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: A systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetologica, 58(1):39-46. https://doi.org/10.1007/s00592-020-01590-w

Pantanetti, P., Cangelosi, G., Alberti, S., Di Marco, S., Michetti, G., Cerasoli, G., et al. (2024). Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Frontiers in Endocrinology (Lausanne), 15:1394506. https://doi.org/10.3389/fendo.2024.1394506

Patel, T., Nageeta, F., Sohail, R., Butt, T.S., Ganesan, S., Madhurita, F., et al. (2023). Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Annals of Medicine, 55(2):2239830. https://doi.org/10.1080/07853890.2023.2239830

Pantanetti, P., Ronconi, V., Sguanci, M., Palomares, S. M., Mancin, S., Tartaglia, F. C. et al. (2024). Oral semaglutide in type 2 diabetes: Clinical-metabolic outcomes and quality of life in real-world practice. J Clin Med, 13(16):4752. https://doi: 10.3390/jcm13164752

Rea, F., Savare, L., Valsassina, V., Ciardullo, S., Perseghin, G., Corrao, G., et al. (2023). Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. Cardiovascular Diabetology, 22(1):53. https://doi.org/10.1186/s12933-023-01786-8

Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N. (2023). Patient preferences for newer oral therapies in type 2 diabetes. International Journal of Cardiology, 371:526-532. https://doi.org/10.1016/j.ijcard.2022.09.009

Seidu, S., Cos, X., Brunton, S., Harris, S.B., Jansson, S.P.O., Mata- Cases, M., et al. (2022). 2022 update to the position statement by Primary Care Diabetes Europe: A disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 16(2):223-244. https://doi.org/10.1016/j.pcd.2022.02.002

Smith, I., Hardy, E., Mitchell, S., & Batson, S. (2022). Semaglutide 2.4 Mg for the management of overweight and obesity: Systematic literature review and meta-analysis. Diabetes Metabolic Syndrome and Obesity, 15:3961-3987. https://doi.org/10.2147/DMSO.S392952

Solar, O., & Irwin, A. (2010). A Conceptual Framework for Action on the Social Determinants of Health. WHO Document Production Services. Switzerland: WHO.

Tamhane, S., Rodriguez-Gutierrez, R., Hargraves, I., & Montori, V.M. (2015). Shared decision-making in diabetes care. Current Diabetes Reports, 15(12):112. https://doi.org/10.1007/s11892-015-0688-0

Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019). SGLT2 Inhibitors: A review of their antidiabetic and cardioprotective effects. International Journal of Environmental Research and Public Health, 16(16):2965. https://doi.org/10.3390/ijerph16162965

Turchetti, G., Spadoni, E., & Geisler, E. (2010). Health Technology Assessment. Available from: ht t p s : / / i e e e x p l o r e . ieee.org/abstract/document/5463009 [Last accessed on 2018 Apr 11].

Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021). Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Therapy, 12(5):1475-1489. https://doi.org/10.1007/s13300-021-01053-7

Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L.J., Davitkov, P., et al. (2021). Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: A systematic review and network meta-analysis. EClinicalMedicine, 42:101213. https://doi.org/10.1016/j.eclinm.2021.101213

Weeda, E.R., Muraoka, A.K., Brock, M.D., & Cannon, J.M. (2021). Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis. International Journal of Clinical Practice, 75(9):e14060. https://doi.org/10.1111/ijcp.14060

Weiss, T., Carr, R.D., Pal, S., Yang, L., Sawhney, B., Boggs, R., et al. (2020). Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence, 14:2337-2345. https://doi.org/10.2147/PPA.S277676

Wilson, R.B., Lathigara, D., & Kaushal, D. (2023). Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. International Journal of Molecular Sciences, 24(7):6192. https://doi.org/10.3390/ijms24076192

Wu, S., Lu, W., Chen, Z., Dai, Y., Chen, K., & Zhang, S. (2022). Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: A systematic review and meta-analysis of randomized controlled trials. Diabetology and Metabolic Syndrome, 14(1):195. https://doi.org/10.1186/s13098-022-00970-2

Xie, Z., Li, J., Yang, S., Deng, W., & Chen, J. (2022). A health technology assessment based on Chinese guidelines: glucagon-like peptide-1 receptor agonist in the treatment of type 2 diabetes complicated with cardiovascular disease. Therapeutics and Clinical Risk Management, 18:889-900. https://doi.org/10.2147/TCRM.S375067

Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022). Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: A systematic review. Clinical Epidemiology, 14:1463-1476. https://doi.org/10.2147/CLEP.S391819

Yuan, X., Gao, Z., Yang, C., Duan, K., Ren, L., & Song, G. (2023). Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: A network meta-analysis. Frontiers in Endocrinology (Lausanne), 14:1170881. https://doi.org/10.3389/fendo.2023.1170881

Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., et al. (2023). GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: A system review and network meta-analysis. Frontiers in Endocrinology (Lausanne), 14:1149328. https://doi.org/10.3389/fendo.2023.1149328

Zhu, J., Zhou, Y., Li, Q., & Wang, G. (2023). Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: A systematic review. Advances in Therapy, 40(10):4216-4235. https://doi.org/10.1007/s12325-023-02612-z

World Obesity Federation. Obesity: Missing the 2025 global targets. Trends, Costs and CountryReports. (2020). Available from: https://s3-eu-west-1.amazonaws.com/wof-files/970_-_ WOF_Missing_the_2025_Global_Targets_Report_ART.pdf [Last accessed on 2025 Mar 18].